Loading...
•
Dec 31, 2021
InspireMD Q4 2021 Earnings Report
Reported increased revenue driven by CGuard EPS and increased gross profit due to distributor settlement impact, with operating expenses rising due to FDA study and market expansion.
Key Takeaways
InspireMD reported a significant increase in revenue for Q4 2021, driven by strong growth in CGuard EPS sales. The company's gross profit improved compared to the previous year. Operating expenses also increased due to investments in a U.S. FDA study and market expansion.
Revenue increased by 773.8% to $1,380,000 compared to Q4 2020.
CGuard EPS revenue increased by 87.5% to $1,291,000 compared to Q4 2020.
Gross profit increased to $294,000 compared to a gross loss of $390,000 in Q4 2020.
Net loss totaled $4,097,000, or $0.53 per share, compared to a net loss of $3,853,000, or $1.52 per share, in Q4 2020.
InspireMD
InspireMD
InspireMD Revenue by Segment
Revenue by Segment
CGuard EPS Revenue
CapyFin.com Forward Guidance
InspireMD anticipates growth of CGuard, pipeline development, and evidence demonstrating CGuard's superiority in clinical performance.
Positive Outlook
- Anticipating growth of CGuard
- Continuing pipeline development
- Advancing the growing body of evidence demonstrating CGuard’s superiority in clinical performance amongst all other stent options and surgery